Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WSJER
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
NV102
|
|||||
| Synonyms |
DoxantiCD19; Anti-CD19 antibody-conjugated doxorubicin liposomal nanoparticle; NV-102; NV 102
Click to Show/Hide
|
|||||
| Organization |
NanoValent Pharmaceuticals, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 3 Indication(s)
Acute lymphoblastic leukemia [ICD11:2B33]
Clinical candidate
Acute myeloid leukaemia [ICD11:2A60]
Clinical candidate
Lymphoid leukaemia [ICD11:2B33]
Clinical candidate
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
Doxorubicin
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.